Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.
Protalix BioTherapeutics, Inc. develops, manufactures and commercializes recombinant therapeutic proteins for rare diseases using its proprietary plant cell-based expression system, ProCellEx®. The company’s recurring news includes financial results, business updates, regulatory developments for Elfabrio® in Fabry disease, and commercial or partnership activity tied to approved enzyme replacement therapies.
Company updates also cover pipeline programs such as PRX-115, a recombinant PEGylated uricase candidate for uncontrolled gout, and PRX-119, a long-acting DNase I program associated with rare kidney disease research. Protalix also reports on collaborations involving RNA-based therapeutic discovery and on its licensed relationship with Pfizer for taliglucerase alfa, Elelyso®, for Gaucher disease outside Protalix-retained rights in Brazil.
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical firm, will host an in-person investor day on June 26, 2024, at the Lotte Palace New York Hotel. The event will begin at 8:30 a.m. EDT. Key opinion leaders, including Aleš Linhart of Charles University and Naomi Schlesinger of the University of Utah, will discuss the treatment landscapes for Fabry disease and uncontrolled gout, respectively. Special focus will be on clinical results for Elfabrio® (pegunigalsidase alfa) and PRX-115. Protalix's CEO, Dror Bashan, will also present a corporate overview. A live Q&A session will follow the presentations.
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins via its ProCellEx® plant cell-based system, announced its participation at the 2024 BIO International Convention in San Diego, California. The convention, hosted by the Biotechnology Innovation Organization (BIO), is the largest industry event, gathering global biotech and biopharmaceutical executives. Dror Bashan, President and CEO of Protalix, will present on June 3, 2024, at 2:30 PM PDT in Theater 1, providing updates on corporate developments to industry leaders and investors.
Protalix BioTherapeutics, Inc. (PLX) reported financial results for Q1 2024, highlighting encouraging top-line results from the phase I clinical trial of its uricase candidate, PRX-115. The company plans to expand the trial into a phase II study. Despite a decrease in revenues, Protalix remains focused on research and development efforts to build its product pipeline. The company's cash position is strong, enabling it to repay convertible notes due in September 2024 and sustain ongoing operations.
Protalix BioTherapeutics, Inc. will announce its financial results for the first quarter of 2024 on May 10, 2024, along with a business and clinical update. The company focuses on developing and commercializing recombinant therapeutic proteins. Investors can join the conference call and webcast to discuss the results and recent developments. The call details are provided for easy access.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.